Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury
| Status: | Completed |
|---|---|
| Conditions: | Depression, Hospital, Orthopedic |
| Therapuetic Areas: | Psychiatry / Psychology, Orthopedics / Podiatry, Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | June 2008 |
| End Date: | August 2011 |
| Contact: | Linda Berlin, MA |
| Email: | lspencer@umich.edu |
| Phone: | (734) 763-0971 |
This study proposes to test the efficacy of Venlafaxine HCI in reducing mild to moderate
symptoms of depression among persons with Spinal Cord Injury (SCI). This study recruits
either traumatic or non-traumatic injured persons with SCI living in the community.
symptoms of depression among persons with Spinal Cord Injury (SCI). This study recruits
either traumatic or non-traumatic injured persons with SCI living in the community.
The successes of psychological and pharmacological modes of intervention in treating
depression, both alone and combined, are well documented in the literature. While a great
deal of research has identified specific clinical indications for many antidepressants
currently available in the general population, little is known about the clinical
indications of these agents in SCI. This study is proposed to test the benefits of
Venlafaxine HCI (Effexor XR) for reducing mild to moderate symptoms of depression among
people with SCI. As a secondary outcome, this study will assess also the benefits of this
medication in reducing severity of symptoms of pain, and enhancing subjects' perceived
health and participation in the community. The intervention will last 12 weeks and there
will be 13 assessments and data collection points. Data will be collected at 26 weeks also.
Eight face to face contacts are anticipated.
depression, both alone and combined, are well documented in the literature. While a great
deal of research has identified specific clinical indications for many antidepressants
currently available in the general population, little is known about the clinical
indications of these agents in SCI. This study is proposed to test the benefits of
Venlafaxine HCI (Effexor XR) for reducing mild to moderate symptoms of depression among
people with SCI. As a secondary outcome, this study will assess also the benefits of this
medication in reducing severity of symptoms of pain, and enhancing subjects' perceived
health and participation in the community. The intervention will last 12 weeks and there
will be 13 assessments and data collection points. Data will be collected at 26 weeks also.
Eight face to face contacts are anticipated.
Inclusion Criteria:
- Having incurred a SCI at least one year prior to enrollment
- Neurological impairment ASIA Grades A-D with some associated functional limitations
- PHQ 9 scores of 5 - 14 (mild to moderate symptom severity)
- English speaker
- Age 18 years or older
- Completed informed consent and agreement to release protected health information
(PHI) under the rules established by HIPAA
- Able to communicate with study personnel
Exclusion Criteria:
- Presence of cognitive deficits precluding and giving informed consent and completion
of survey based assessment tools
- Psychiatric contraindications (suicidal ideation, history of suicidal attempts,
alcohol and drug dependency, other psychiatric diagnosis including bipolar disorder)
- Medical contraindications (terminal illness or unstable medical condition as
determined by medical history and/or examination)
- Pregnant or unwilling to use birth control if female and sexually active
- Presence of glaucoma
- Prior use of study drug without success or being treated with another antidepressant
medication
- Presence of glaucoma
- Engagement in another experimental study within 30 days
- Expectation of major surgery within the following 12 weeks
We found this trial at
1
site
Click here to add this to my saved trials
